WHITE BEAR LAKE, Minn., Dec. 10, 2025 — Envoy Medical announced the successful first set of activations in the final stage of its pivotal clinical study evaluating the fully implanted Acclaim® cochlear implant, a first-of-its-kind investigational device designed to leverage the natural ear rather than external microphones. Conducted across two of seven clinical sites, the milestone underscores growing momentum behind the Company’s innovative, fully implanted approach to restoring hearing for patients with severe to profound sensorineural loss.
Science Significance
The Acclaim® cochlear implant represents a substantial scientific leap forward in auditory restoration by integrating a proprietary piezoelectric sensor system that uses the body’s natural anatomy to capture sound, eliminating the need for external components. This architecture enables a continuous, discreet hearing experience and introduces a multi-day rechargeable battery system with a replaceable pack, advancing long-term usability. Early activation data—while not publicly reportable during the blind phase—indicate no serious adverse events, reinforcing the scientific promise and physiological compatibility of the fully implanted design. By moving beyond microphone-based sound capture, the technology attempts to deliver a more natural auditory signal and reduce issues associated with wind noise, device visibility, and environmental interference.
Regulatory Significance
The Acclaim® implant carries Breakthrough Device Designation from the FDA, reflecting its potential to meet an unmet medical need for adults with sensorineural hearing loss not adequately addressed by hearing aids. The successful initiation of activations marks a crucial step toward Premarket Approval (PMA) preparation. With full enrollment anticipated in early 2026, the pivotal trial progresses on a timeline aligned with regulatory expectations for Class III implantable devices. Envoy’s adherence to stringent investigational requirements, combined with clean safety observations to date, strengthens its position as a pioneering contender in the next generation of implanted hearing solutions. The trial’s scope, multi-site structure, and ongoing data collection will form the foundation for regulated commercial introduction in the United States.
Business Significance
Advertisement
Envoy CEO Brent Lucas highlighted the accelerating pace of enrollment and the strong demand signals from clinicians and prospective recipients. The device’s unique hardware architecture, absence of external wearables, and patient-centric design elevate Envoy’s competitive differentiation in a global hearing-health market seeking more discreet and durable solutions. The Company’s NASDAQ: COCH listing and ongoing investor engagement position it to capitalize on the expected commercial interest upon PMA approval. With intellectual property surrounding its piezoelectric sensor platform and fully implanted system, Envoy stands to secure a leadership foothold in the premium cochlear implant segment, where technology innovation and patient experience are major drivers of adoption.
Patients’ Significance
For patients, the Acclaim® cochlear implant promises a transformational shift from traditional partially implanted systems. By removing external processors, magnets, and daily wear components, the technology aims to deliver true 24/7 hearing capability in a fully implanted format. Individuals who struggle with device maintenance, cosmetic concerns, lifestyle limitations, or discomfort from external hardware may greatly benefit from this approach. The ability to recharge less frequently and replace the battery independently enhances long-term convenience and reduces overall burden of care. If the pivotal trial continues to meet safety and performance targets, this device could redefine quality-of-life expectations for adults living with severe hearing loss.
Policy Significance
The progress of Envoy’s pivotal trial intersects with evolving U.S. regulatory initiatives supporting breakthrough hearing technologies, innovation in medical devices, and improved patient access pathways. As agencies continue to emphasize outcomes-driven evaluation for devices addressing significant unmet needs, fully implanted systems like Acclaim® may catalyze new policy considerations around reimbursement models, long-term follow-up requirements, and standards for implantable auditory technologies. The study’s advancement also supports broader national conversations surrounding hearing-health equity, early intervention, and technology-driven accessibility for aging populations.
Envoy Medical’s latest clinical milestone reinforces the momentum behind its fully implanted cochlear implant technology as it moves toward full enrollment and eventual regulatory submission. With strong scientific footing, a favorable safety profile to date, escalating market interest, and meaningful implications for patients, the Acclaim® pivotal study positions the Company at the forefront of next-generation hearing innovation. Envoy’s continued progress signals a potentially transformative shift for the hearing-health landscape as fully implanted systems move closer to commercial reality.
Source: Envoy Medical Inc. press release
